CCS 2023 Cardiorenal Risk Reduction Guidelines: GLP-1 RA and SGLT2i

Zusammenfassung

CARDIORENAL RISK REDUCTION IN ADULTS Cardiorenal Risk Reduction in Adults GUIDELINES POCKET GUIDE This pocket guide is a quick-reference tool that features diagnostic and management recommendations based on the 2022 Canadian Cardiovascular Society (CCS) Guideline for Use of GLP-1 Receptor Agonists and SGLT2 Inhibitors for Cardiorenal Risk Reduction in Adults. These recommendations are intended to provide a reasonable and practical approach to care for physicians, pharmacists, nurse

Kerninformationen

A1C, glycosylated hemoglobin; ASCVD, atherosclerotic cardiovascular disease, CV, cardiovascular; eGFR, estimated glomerular filtration rate; GLP-1RA, glucagon-like peptide-1 receptor agonists; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; SGLT2i, sodium-glu...

GLP-1RA or SGLT2i to reduce the risk of all-cause, or CV mortality or MACE. StrongModerate b. SGLT2i to reduce the risk of hospitalization for HF or the composite of significant decline in eGFR, progression to end-stage kidney disease or death due to kidney disease. StrongModerate c. GLP-1RA to red...

See Figure 2 for mitigation strategies. 8 Insulin or Insulin Secretagogues? YESNO • Add GLP-1RA or SGLT2i • Reduce insulin secretagogue by 50% or stop • If on insulin, decrease by 10%-20% and/or consult diabetes team • Counsel on hypoglycemia • Add GLP-1RA or SGLT2i • Low risk of hypoglycem...

Fragen zu diesem Thema?

ClariMed durchsucht alle Leitlinien mit KI und liefert quellenbasierte Antworten in Sekunden.

Jetzt auf ClariMed suchen